DeepCyte announced a $1.5 M seed round to launch its AI-driven single‑cell toxicology platform, Meta...
The AMW Read
This is an incremental update regarding a new entrant in the tech-bio/toxicology sub-segment; the $1.5M seed round does not trigger cross.§D due to the <$500M threshold.
NoveltySignificance
Healthcare & Bio · Player Map
DeepCyte announced a $1.5 M seed round to launch its AI-driven single‑cell toxicology platform, MetaCore, aimed at predicting drug safety at the cellular level. This early‑stage capital will accelerate model training on human cell data, potentially reducing late‑stage attrition for pharma pipelines. As single‑cell insights become a standard in drug development, DeepCyte’s financing signals growing investor confidence in tech‑bio solutions that de‑risk toxicity early on. 🚀